Newland released its semi-annual performance, with a net profit attributable to the parent company of 78.03 million yuan, a year-on-year decrease of 30.01%
Newland released its 2025 semi-annual performance, with revenue of 359 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of the parent company was 78.03 million yuan, a year-on-year decrease of 30.01%; net profit excluding non-recurring items was 71.79 million yuan, a year-on-year decrease of 31.56%; basic earnings per share were 0.20 yuan. Despite the overall decline in performance, revenue from toluenesulfonic acid increased by 13.16% year-on-year, and the company has competitive advantages in the pharmaceutical and high-purity markets, actively expanding into high-end application fields
According to the Zhitong Finance APP, Newland (301277.SZ) disclosed its semi-annual report for 2025, reporting revenue of 359 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of the listed company was 78.03 million yuan, a year-on-year decrease of 30.01%; net profit excluding non-recurring items was 71.79 million yuan, a year-on-year decrease of 31.56%; basic earnings per share were 0.20 yuan.
During the reporting period, revenue from toluenesulfonic acid increased by 13.16% year-on-year, mainly due to the company's strong competitive advantage in the pharmaceutical-grade and high-purity market, achieved through continuous technological research and development, process innovation, and an excellent quality management system. With the widespread use of toluenesulfonic acid in pharmaceuticals and high-end electronic chemicals, the company is actively expanding its market customers in high-end application fields and continuously increasing its market share in the high-end market
